Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up

Owen, Roger G. et al.

Cornell Ecommons · Other

wcm library coordinated deposit, humans, waldenstrom macroglobulinemia/drug therapy/mortality, pyrazines/therapeutic use/adverse effects/administration & dosage/pharmacology, benzamides/therapeutic use/adverse effects/administration & dosage/pharmacology, follow-up studies, female, aged

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up

Related documents